Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661958 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris
A Phase 2 study, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 726
- Enrollment target
NCT02661958: Completed Phase 2 study, sponsored by Sol-Gel Technologies.
NCT02661958 is a Phase 2 study that has completed, run by Sol-Gel Technologies. The registered enrollment target is 726 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (446% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02661958, a Phase 2 study, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 726 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the superiority in efficacy and assess safety and tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active components or the vehicle for the treatment of acne.
Primary Outcome
Proportion of subjects with an assessment of clear or almost clear with at least a 2-grade improvement in IGA at Week 12
Interventions
- DRUG S6G5T-3
- DRUG S6G5T-1
- DRUG S6G5T-5
- DRUG S6G5T-6
- DRUG S6G5T-7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 726 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-10 |
| Phase | Phase 2 |
What the finished NCT02661958 record still lists
NCT02661958 is an interventional study that assigns participants to a tested intervention. The registered 726 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (446% higher).
The record links to 0 conditions, and to 5 interventions - of which S6G5T-3 is the first listed.
NCT02661958 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02661958 about?
NCT02661958 is a clinical study titled "Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris". The purpose of this study is to evaluate the superiority in efficacy and assess safety and tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active components or the vehicle for the treatment of acne.
What is the current status of trial NCT02661958?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 726 participants. The study started on 2016-05. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02661958?
The interventions under investigation include: S6G5T-3 (DRUG), S6G5T-1 (DRUG), S6G5T-5 (DRUG), S6G5T-6 (DRUG), S6G5T-7 (DRUG).
Who is sponsoring clinical trial NCT02661958?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02661958's enrollment target sits among peer trials
726 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06731478 · 726 participants · Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia